Company profile
HELUS PHARMA INC.
NASDAQ:HELPBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| DEUPSILOCIN | phase3 | — | 4 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06564818 | phase3 | active_not_recruiting | 2024-12-17 | 2026-09-04 | Cybin IRL Limited | "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" |
| NCT06793397 | phase3 | recruiting | 2025-12-10 | 2027-06-07 | Cybin IRL Limited | A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder |
| NCT06051721 | phase2 | completed | 2024-05-10 | 2025-10-14 | Cybin IRL Limited | A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD) |
| NCT05385783 | phase1_2 | completed | 2022-08-02 | 2023-10-16 | Cybin IRL Limited | A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder |
| NCT05594667 | phase2 | withdrawn | 2023-01-01 | 2023-03-14 | Cybin Therapeutics Inc. | Effect of SSRIs on Response to Psilocybin Therapy |
FDA applications (0)
No records yet.